Health TrialsbyHealthPanel

Blood Samples Were Taken From Patients Undergoing Oncological Treatment in Order to Validate the TST79 Molecular Test

ConditionCancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGrand Hôpital de Charleroi

About this trial

The pathological anatomy laboratory, which is managed by the IPG, would involve monitoring patients being treated for cancer and receiving care at the GHDC in order to take blood samples from those in whom the presence of plasma ctDNA carrying a mutation in a specific gene is suspected - a mutation detectable by the TST79 test.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

lung adenocarcinoma

colorectal adenocarcinoma

breast carcinoma

prostate adenocarcinoma

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Gene-alteration pair (G-A)

    Genetic

    Point mutations, small insertions or deletions (indels), gene fusions, copy number amplifications.

Treatment groups

15 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Group A: 2 patients with POLE-mutated endometrial cancerExperimental treatment 1 intervention
Group B: 2-4 patients with lung adenocarcinoma involving rare gene fusionsExperimental treatment 1 intervention
Group C: 1-2 patients with lung adenocarcinoma with a point mutation in EGFRExperimental treatment 1 intervention
Group D: 2-3 patients with GIST (gastrointestinal stromal tumour) harbouring a KIT mutationExperimental treatment 1 intervention
Group E: 2-3 patients with clear-cell renal cell carcinoma with a VHL mutationExperimental treatment 1 intervention
Group F: 1-2 patients with breast cancer with ERBB2 amplificationExperimental treatment 1 intervention
Group G: 2-3 patients with high-grade ovarian carcinoma and a BRCA1 or BRCA2 mutationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

To validate and accredit the TST79 test on plasma samples within the hospital's pathology laboratory

The aim is to extend tumour DNA sequencing to circulating tumour DNA (ctDNA), which is present in the plasma of cancer patients.

Time frame
Through study completion, an average of two years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Grand Hôpital de Charleroi

Lead sponsor

Institut de Pathologie et de Génétique Charleroi

Collaborator

Source ClinicalTrials.gov
Apply now